For small and medium pharmaceutical manufacturers, compliance can sometimes feel like a challenge reserved for large pharma companies with dedicated regulatory teams, extensive infrastructure, and large compliance budgets. However, Good Manufacturing Practices (GMP) compliance is not limited to large pharmaceutical manufacturers. Small and medium pharma manufacturers also need to maintain appropriate GMP systems to ensure the quality, safety, and consistency of their products.
This has become even more important in India following the implementation of the revised Schedule M requirements under the Drugs Rules, 1945. The revised framework strengthened requirements related to Good Manufacturing Practices as well as premises, plant, and equipment for pharmaceutical products. While larger manufacturers were required to implement the revised requirements earlier, small and medium manufacturers were given a conditional extension, with the extended implementation timeline ending on 31 December 2025. The revised requirements are therefore particularly important for small and medium manufacturers operating in 2026.
So, do small and medium pharma manufacturers need GMP compliance?
Yes. GMP compliance is essential for pharmaceutical manufacturers, regardless of whether the business is large, medium, or relatively small. The scale of the business may influence the resources required for implementation, but it does not remove the underlying responsibility to manufacture medicines consistently and according to applicable quality and regulatory requirements.
In this article, we will explain why GMP compliance matters for small and medium pharmaceutical manufacturers, what revised Schedule M means for them, the major areas they need to review, and how businesses can prepare for GMP inspections and compliance requirements.
What Is GMP Compliance?
Good Manufacturing Practices, commonly known as GMP, are quality-management principles and manufacturing requirements designed to ensure that pharmaceutical products are consistently produced and controlled according to appropriate quality standards.
GMP is not simply a certificate or a document kept inside a company's compliance file. It involves the practical systems, procedures, facilities, equipment, personnel, documentation, quality controls, and manufacturing processes used by a pharmaceutical company.
The revised Schedule M framework requires manufacturers to establish appropriate systems and procedures that are documented and maintained for inspection and reference. It also emphasizes a pharmaceutical quality system and quality risk management.
For a small or medium pharmaceutical manufacturer, this means GMP compliance can affect areas such as:
- Manufacturing processes
- Quality control
- Quality assurance
- Documentation
- Standard Operating Procedures (SOPs)
- Personnel training
- Equipment qualification
- Validation
- HVAC and environmental controls
- Water and utility systems
- Laboratory facilities
- Storage and material handling
- Batch records
- Deviation management
- Change control
- Corrective and Preventive Actions (CAPA)
- Internal audits
- Quality risk management
The exact requirements applicable to a business depend on its manufacturing activities, products, facilities, licences, and applicable regulatory requirements.
Do Small and Medium Pharma Manufacturers Need GMP Compliance?
Yes. Being a small or medium manufacturer does not automatically exempt a pharmaceutical company from GMP requirements.
One of the important developments for Indian pharmaceutical manufacturers was the notification of revised Schedule M on 28 December 2023. The revised provisions expanded the earlier GMP framework to include requirements concerning premises, plant, and equipment for pharmaceutical products.
The government initially provided different implementation timelines based on manufacturer size. Large manufacturers with turnover above ₹250 crore were required to implement the revised requirements earlier, while small and medium manufacturers with turnover of ₹250 crore or less were given additional time subject to specified conditions. The conditional extension ultimately allowed eligible small and medium manufacturers to implement the revised requirements by 31 December 2025.
As of 2026, therefore, small and medium pharmaceutical manufacturers should not treat GMP compliance as something that can simply be postponed because of their business size.
Why Is GMP Compliance Important for Small and Medium Pharma Companies?
GMP compliance is particularly important for smaller pharmaceutical manufacturers because regulatory deficiencies can affect manufacturing continuity, product quality, business reputation, and future growth.
1. It Helps Maintain Consistent Product Quality
Pharmaceutical products directly affect patient health. Variations in manufacturing processes, contamination, incorrect labelling, inadequate testing, or poor storage conditions can compromise product quality.
GMP systems help manufacturers establish controlled and repeatable processes.
For a growing pharmaceutical company, implementing these controls early can also make it easier to scale production without sacrificing quality.
2. It Supports Regulatory Compliance
Pharmaceutical manufacturing is highly regulated in India.
Manufacturers may be inspected by regulatory authorities to assess compliance with applicable requirements. Government information published in 2025 stated that CDSCO and state regulators had conducted risk-based inspections of hundreds of drug manufacturing and testing units, with enforcement actions including stop-production orders, licence suspensions or cancellations, warning letters, and show-cause notices depending on the circumstances.
This demonstrates why manufacturers should not wait for an inspection before identifying compliance gaps.
3. It Reduces the Risk of Manufacturing Problems
A strong GMP system can help identify weaknesses before they become serious manufacturing or quality problems.
For example, a manufacturer may discover during a GMP gap assessment that:
- SOPs are incomplete
- Equipment qualification records are missing
- Cleaning procedures are inadequately documented
- Personnel training records are inconsistent
- Batch manufacturing records need improvement
- HVAC controls require upgrading
- Laboratory equipment documentation is incomplete
- Deviations are not properly investigated
- CAPA procedures are weak
Identifying such gaps early allows management to create a structured corrective action plan.
4. It Builds Customer and Market Confidence
Pharmaceutical companies increasingly need to demonstrate their quality systems to business partners, distributors, institutional buyers, contract manufacturing clients, and international customers.
A structured GMP system can strengthen confidence in the manufacturer's ability to consistently produce pharmaceutical products under controlled conditions.
5. It Supports Business Expansion
A small pharmaceutical manufacturer may eventually want to:
- Add new products
- Increase manufacturing capacity
- Enter new states
- Work with larger pharmaceutical companies
- Enter export markets
- Obtain additional approvals
- Establish contract manufacturing relationships
Weak compliance systems can become a barrier to such expansion.
Building a strong GMP framework can therefore be viewed not only as a regulatory responsibility but also as part of long-term business development.
What Does Revised Schedule M Mean for Small and Medium Manufacturers?
The revised Schedule M requirements are particularly significant because they go beyond a narrow understanding of GMP.
The updated framework covers Good Manufacturing Practices and requirements relating to premises, plant, and equipment for pharmaceutical products. It also emphasizes the pharmaceutical quality system, quality risk management, documentation, management responsibility, and controlled manufacturing operations.
For small and medium manufacturers, compliance may therefore require improvements in multiple areas rather than simply preparing a few documents.
Depending on the manufacturing operation, businesses may need to evaluate:
Pharmaceutical Quality System
Management should establish an effective quality system with clearly defined responsibilities and adequate resources.
The revised Schedule M specifically places ultimate responsibility on senior management for ensuring that an effective pharmaceutical quality system is established and adequately resourced.
Premises and Facility
Manufacturers need to assess whether their facilities are appropriately designed and maintained for the products and processes involved.
This may include evaluating:
- Production areas
- Material movement
- Personnel movement
- Storage areas
- Segregation requirements
- Clean areas
- Sanitation
- Environmental controls
Equipment
Equipment should be appropriate for its intended purpose and maintained under controlled procedures.
Manufacturers may need to review:
- Equipment qualification
- Calibration
- Preventive maintenance
- Cleaning
- Operating procedures
- Equipment records
HVAC and Environmental Controls
For relevant pharmaceutical manufacturing operations, HVAC and environmental controls can be critical components of product quality.
Small manufacturers should not assume that existing systems automatically satisfy revised requirements. A technical assessment may be necessary to identify gaps.
Laboratory and Testing Facilities
Quality control laboratories should have appropriate facilities, equipment, procedures, documentation, and qualified personnel according to applicable requirements.
Documentation
Documentation is one of the most important components of GMP compliance.
Manufacturers may need controlled documentation covering areas such as:
- SOPs
- Batch manufacturing records
- Testing procedures
- Cleaning records
- Equipment records
- Training records
- Deviation reports
- CAPA
- Change control
- Validation
- Qualification
- Quality risk management
A facility may have good infrastructure but still face compliance issues if its documentation does not demonstrate that processes are consistently controlled.
Can a Small Pharma Manufacturer Afford GMP Compliance?
This is one of the biggest concerns for small and medium pharmaceutical businesses.
GMP implementation can require investment in infrastructure, equipment, laboratory systems, utilities, documentation, training, and quality personnel. However, the cost should be viewed in relation to the risks of non-compliance and the long-term requirements of pharmaceutical manufacturing.
The government has also introduced support mechanisms aimed at pharmaceutical technology and quality upgrades. For example, the revamped Pharmaceuticals Technology Upgradation Assistance Scheme was designed to support pharmaceutical manufacturers in upgrading technology and aligning with revised Schedule M and WHO-GMP standards. Eligible activities can include HVAC systems, water and steam utilities, testing laboratories, stability chambers, clean rooms, effluent treatment, and waste management.
This indicates that infrastructure and quality upgrades are recognized as an important part of strengthening India's pharmaceutical manufacturing sector.
The practical approach for a smaller manufacturer is not necessarily to upgrade everything at once.
Instead, management can begin with a structured GMP gap assessment.
What Is a GMP Gap Assessment?
A GMP gap assessment compares the manufacturer's existing systems and infrastructure against applicable GMP requirements.
It helps answer questions such as:
- Which GMP requirements are already being met?
- Which requirements are partially implemented?
- Which areas require immediate correction?
- Which infrastructure upgrades are necessary?
- Which documents need to be created or revised?
- What training is required?
- What should be the priority for implementation?
For small and medium pharmaceutical manufacturers, this can be one of the most useful first steps because it turns a broad compliance requirement into an actionable plan.
A gap assessment may examine areas including:
- Premises
- Plant and equipment
- HVAC systems
- Utilities
- Quality control laboratories
- Documentation
- Personnel
- Production systems
- Quality assurance
- Validation and qualification
- Storage and distribution
- Sanitation and hygiene
- Deviation and CAPA systems
- Change control
- Internal audits
The 2025 extension framework itself required eligible manufacturers seeking additional time to provide an upgradation plan based on a section-wise gap analysis, illustrating the importance of structured assessment for Schedule M implementation.
What Happens If a Small Pharma Manufacturer Is Not GMP Compliant?
Non-compliance can have different consequences depending on the nature and severity of the deficiency.
Potential consequences can include:
- Regulatory observations
- Show-cause notices
- Corrective action requirements
- Manufacturing restrictions
- Stop-production directions
- Licence suspension
- Licence cancellation
- Product recalls
- Financial losses
- Customer loss
- Damage to business reputation
Government reporting has confirmed that regulatory enforcement can include stop production orders, stop testing orders, licence suspension or cancellation, warning letters, and show-cause notices depending on the findings.
Therefore, waiting until a serious regulatory issue occurs can be considerably more expensive than proactively identifying and addressing compliance gaps.
How Can Small and Medium Pharma Manufacturers Prepare for GMP Compliance?
A practical GMP compliance strategy can be divided into several stages.
Step 1: Identify Applicable Requirements
First, determine which GMP and regulatory requirements apply to the specific manufacturing activity, products, facility, and licence.
Step 2: Conduct a GMP Gap Assessment
Review the existing facility, systems, equipment, documentation, personnel, and quality processes against applicable requirements.
Step 3: Prepare a Compliance Roadmap
Create a prioritized action plan.
The roadmap should identify:
- Existing gaps
- Required corrective actions
- Responsible departments
- Required investment
- Target completion dates
- Documentation requirements
Step 4: Upgrade Infrastructure
Where necessary, address infrastructure-related gaps involving premises, HVAC, utilities, equipment, laboratory systems, storage, and other relevant areas.
Step 5: Develop and Update Documentation
Prepare or revise SOPs, quality manuals, records, batch documents, validation documents, training records, and other required documentation.
Step 6: Train Employees
Employees should understand the procedures relevant to their responsibilities.
GMP compliance is not only a management responsibility. Manufacturing, quality control, quality assurance, engineering, warehouse, and other relevant personnel all have roles to play.
Step 7: Conduct Internal Audits
Before a regulatory inspection, an internal GMP audit can help identify unresolved issues.
A mock inspection can also help management understand whether employees can demonstrate compliance through actual records and procedures.
Step 8: Maintain Continuous Compliance
GMP should not be treated as a one-time project.
Processes need to be monitored, documented, reviewed, and improved continuously.
GMP Compliance Is More Than Getting a Certificate
A common misunderstanding among smaller businesses is that GMP compliance is simply about obtaining a certificate.
In reality, GMP is an ongoing quality system.
A manufacturer may have documentation in place but still have practical implementation gaps. Similarly, a company may have good manufacturing infrastructure but inadequate records demonstrating that processes are consistently followed.
Effective GMP compliance therefore requires alignment between:
People + Processes + Premises + Equipment + Documentation + Quality Systems
This is why pharmaceutical manufacturers should focus on actual implementation rather than treating GMP as a paperwork exercise.
How Can a GMP Compliance Consultant Help Small and Medium Pharma Manufacturers?
For smaller pharmaceutical companies without large internal regulatory teams, professional compliance support can simplify the implementation process.
A GMP compliance consultant can potentially assist with areas such as:
- GMP gap assessment
- Compliance planning
- Documentation review
- SOP development
- Quality system implementation
- Facility compliance assessment
- Audit preparation
- Corrective action planning
- Training support
- GMP inspection readiness
For example, Metacorp can help pharmaceutical businesses understand their compliance gaps, organize documentation, and develop a structured approach toward GMP requirements based on their specific operations.
The advantage of taking a structured approach is that the manufacturer can prioritize critical issues rather than spending resources randomly across different compliance areas.
Why GMP Compliance Should Be a Priority in 2026
For small and medium pharmaceutical manufacturers, 2026 is an especially important year for GMP compliance because the conditional extension available to eligible manufacturers with turnover up to ₹250 crore ended on 31 December 2025. Government information published in 2026 confirms that revised Schedule M requirements became applicable to manufacturers below ₹250 crore from 1 January 2026.
This means manufacturers that previously used the additional implementation period should now focus on demonstrating actual compliance rather than simply planning future upgrades.
At the same time, India's regulatory environment continues to emphasize quality monitoring and inspections. CDSCO's ongoing regulatory activities and published updates demonstrate continued attention to pharmaceutical quality and manufacturing compliance.
For businesses planning expansion, exports, new product launches, or partnerships, strengthening GMP systems can also provide a stronger foundation for future growth.
Frequently Asked Questions
1. Is GMP compliance mandatory for small pharmaceutical manufacturers in India?
Yes. Small and medium pharmaceutical manufacturers are also required to comply with applicable GMP requirements. The revised Schedule M requirements became applicable to manufacturers with turnover below ₹250 crore from 1 January 2026 following the conditional extension that ended on 31 December 2025.
2. What is revised Schedule M?
Revised Schedule M is the updated framework under the Drugs Rules, 1945 covering Good Manufacturing Practices along with requirements relating to premises, plant, and equipment for pharmaceutical products. It also addresses areas such as pharmaceutical quality systems and quality risk management.
3. What is a GMP gap assessment?
A GMP gap assessment is a systematic review of a pharmaceutical manufacturer's existing facilities, processes, documentation, equipment, personnel, and quality systems against applicable GMP requirements. It helps identify deficiencies and create a corrective action plan.
4. Can small pharmaceutical manufacturers get help with GMP compliance?
Yes. Manufacturers can work with experienced GMP compliance consultants for services such as gap assessment, documentation, SOP support, implementation planning, audit preparation, and inspection readiness.
5. What can happen if a pharmaceutical manufacturer fails to meet GMP requirements?
Depending on the nature and severity of non-compliance, regulatory consequences can include observations, corrective actions, warning letters, show-cause notices, stop-production directions, licence suspension or cancellation, and other enforcement measures.
Final Thoughts
So, do small and medium pharma manufacturers need GMP compliance?
Absolutely.
Business size does not eliminate the need for appropriate pharmaceutical manufacturing controls. Small and medium manufacturers have the same fundamental responsibility to ensure that their products are manufactured consistently and meet applicable quality and regulatory requirements.
The revised Schedule M framework has made this even more important. With the extended compliance period for eligible small and medium manufacturers ending on 31 December 2025, companies operating in 2026 should evaluate their current GMP status and address any remaining gaps.
The best approach is to avoid waiting for an inspection or regulatory problem. Start with a GMP gap assessment, identify the highest-priority deficiencies, prepare an implementation roadmap, upgrade infrastructure where required, strengthen documentation, train personnel, and establish systems for continuous compliance.
For pharmaceutical manufacturers that need professional assistance, working with an experienced GMP compliance consultant can make the process more structured and manageable.
GMP compliance should not be viewed merely as a regulatory burden. It is an important part of product quality, patient safety, business credibility, and sustainable pharmaceutical growth.